Central Retinal Artery Occlusion
Diagnosis, Emergency Management & Systemic Stroke Work-up
Examination question · ~800 words
What is central retinal artery occlusion? Discuss its aetiology, clinical features, investigations, emergency management, systemic evaluation, prognosis, and complications.
Try to outline your answer mentally before expanding sections below.
Central Retinal Artery Occlusion (CRAO) is an ophthalmic emergency analogous to an ischaemic stroke of the retina. It causes acute ischaemia of the inner retinal layers supplied by the central retinal artery, a branch of the ophthalmic artery. Clinically it presents with sudden, painless, profound monocular visual loss and has major systemic prognostic implications. Irreversible retinal neuronal injury may begin within 90–100 minutes of complete occlusion, so CRAO must be treated as a time-critical ocular and systemic vascular emergency.
Epidemiology
| Parameter | Details |
|---|---|
| Incidence | Approximately 1–2 per 100,000 per year |
| Age | Mean age 60–65 years; uncommon in young patients <40 years |
| Sex | Slight male predominance |
| Laterality | Usually unilateral; >95% are unilateral |
| Systemic association | Most patients have associated vascular risk factors or systemic vascular disease |
Aetiological Classification
| Aetiology | Specific Causes / Associations |
|---|---|
| Embolic | Most common mechanism; usually from carotid atherosclerosis. Other sources include cardiac emboli from atrial fibrillation, valvular disease, paradoxical emboli, cholesterol emboli or Hollenhorst plaques, calcific emboli, and fibrin-platelet emboli. |
| Thrombotic | Atherosclerosis of the central retinal artery, hypercoagulable states such as antiphospholipid syndrome or factor V Leiden, and sickle cell disease. |
| Inflammatory / vasculitic | Giant cell arteritis (GCA) is the critical diagnosis to exclude in older patients. Other causes include polyarteritis nodosa and SLE. |
| Haemodynamic | Severe systemic hypotension, carotid dissection, and ocular hypoperfusion syndrome. |
| Rare / iatrogenic | Post-retrobulbar injection, orbital surgery, cocaine use, oral contraceptive pill association, and syphilis. |
GCA must be excluded in every patient over 50 years with CRAO. Arteritic CRAO is managed with urgent systemic corticosteroids rather than thrombolysis. ESR, CRP, platelet count, and temporal artery biopsy or vascular imaging should be arranged when GCA is suspected.
The central retinal artery (CRA) is an intraorbital branch of the ophthalmic artery from the internal carotid artery. It enters the optic nerve approximately 10–15 mm behind the globe, travels within the optic nerve, pierces the lamina cribrosa, and divides at the optic disc into four major branches supplying the inner retinal layers.
Ischaemic Mechanism
| Aspect | Detail |
|---|---|
| Occlusion | Arterial obstruction causes abrupt cessation of inner retinal blood flow. |
| Time sensitivity | Experimental data suggest irreversible injury may begin after 90–100 minutes of complete occlusion; clinically, treatment is most time-critical within the first few hours. |
| Cellular cascade | ATP depletion, Na+/K+ pump failure, cytotoxic oedema, excitotoxicity, and apoptosis. |
| Inner retina | Becomes oedematous and opaque, producing the classic milky-white retina. |
| Foveal appearance | The fovea is thin and avascular and continues to show choroidal colour, producing the cherry-red spot against the surrounding opaque retina. |
| Cilioretinal artery | Present in approximately 20–35% of eyes; if patent, it may preserve part of the macula and improve visual prognosis. |
The cherry-red spot is not a true red lesion of the fovea. It represents normal choroidal flush seen through the thin fovea, contrasted with the surrounding opaque ischaemic inner retina.
Symptoms
- Sudden, painless, profound monocular visual loss, often count fingers to no perception of light.
- Amaurosis fugax may precede CRAO in 10–15% and should be treated as a TIA-equivalent warning event.
- Partial visual loss may occur when there is cilioretinal artery sparing or branch retinal artery occlusion.
- Relative afferent pupillary defect is usually present in complete CRAO.
Fundus Signs in Acute CRAO
| Sign | Explanation |
|---|---|
| Diffuse retinal whitening | Cytotoxic oedema of the inner retinal layers. |
| Cherry-red spot | Normal choroidal colour seen through the fovea against surrounding retinal whitening. |
| Attenuated retinal arterioles | Narrow, thread-like arterioles with sluggish or segmented flow. |
| Cattle-trucking / box-carring | Segmentation of the blood column due to severe circulatory stasis. |
| Visible embolus | A Hollenhorst plaque may be seen at an arterial bifurcation. |
| Cilioretinal artery sparing | Preserved perfusion of a macular territory if a cilioretinal artery remains patent. |
| Disc pallor | May be mild early; optic atrophy becomes prominent over subsequent weeks. |
Chronic Phase
- Retinal whitening and cherry-red spot usually resolve within 4–6 weeks.
- Progressive optic atrophy develops with a pale disc and persistent arteriolar attenuation.
- OCT shows inner retinal thinning, especially involving the ganglion cell layer and inner plexiform layer.
- Rubeosis iridis and neovascular glaucoma may occur, typically within 1–3 months.
| Type | Mechanism | Visual Acuity | Fundus Findings | Prognosis |
|---|---|---|---|---|
| Complete CRAO | Total central retinal artery occlusion | LP to CF or worse | Diffuse retinal whitening with cherry-red spot | Poorest |
| Incomplete CRAO | Partial occlusion or spontaneous recanalisation | Variable, often CF to 6/60 | Less intense or segmental oedema | Moderate |
| CRAO with cilioretinal artery sparing | CRA occluded but cilioretinal artery remains patent | May be 6/12 to 6/6 in spared territory | Macular or papillomacular sparing | Better |
| Branch retinal artery occlusion | Occlusion of one retinal arterial branch | Depends on macular involvement | Sectoral retinal whitening with corresponding field defect | Good to moderate |
| Transient retinal artery occlusion | Brief occlusion with restored flow | May fully recover | Normal or transient signs | Excellent if systemic cause is treated |
| Ocular ischaemic syndrome | Chronic carotid hypoperfusion | Gradual visual loss | Dilated veins, mid-peripheral haemorrhages, neovascularisation | Variable |
Ocular Investigations
| Investigation | Findings / Purpose |
|---|---|
| Fundus examination | Confirms the clinical diagnosis; identifies cherry-red spot, emboli, arterial attenuation, and cilioretinal artery sparing. |
| Fluorescein angiography | Delayed or absent arterial filling, prolonged arteriovenous transit time, and retinal ischaemia mapping. It is useful but should not delay emergency management. |
| OCT macula | Acute: inner retinal hyperreflectivity and oedema. Chronic: ganglion cell and inner plexiform layer thinning. |
| OCT angiography | Shows flow voids in the superficial capillary plexus; useful in equivocal cases and research settings. |
| Visual field testing | May show complete field loss in CRAO or altitudinal / sectoral defects in BRAO. |
| ERG | Reduced b-wave due to inner retinal ischaemia with relatively preserved a-wave from outer retinal function. |
Mandatory Systemic Work-up
| System | Investigations |
|---|---|
| Cardiovascular | ECG, 24-hour Holter monitoring for paroxysmal atrial fibrillation, echocardiography, carotid Doppler ultrasound, CTA or MRA of carotids. |
| Cerebrovascular | MRI brain with DWI to detect concurrent acute or silent infarction; MRA brain and neck when indicated. |
| Haematological and metabolic | CBC, ESR, CRP, platelet count, coagulation profile, fasting glucose, HbA1c, lipid profile, and uric acid. |
| Young patient work-up | Antiphospholipid antibodies, protein C/S, factor V Leiden, homocysteine, lipoprotein(a), and evaluation for PFO or other embolic sources. |
| Inflammatory / infective | ESR, CRP, temporal artery biopsy if GCA is suspected; ANA, ANCA, VDRL/TPHA when clinically indicated. |
| General | Blood pressure measurement, renal function, and systemic vascular risk assessment. |
CRAO is a stroke-equivalent emergency. All patients require urgent referral to stroke neurology or internal medicine because concurrent cerebral ischaemia may be present and early systemic vascular prevention is essential.
Management is time-critical and has two simultaneous goals: attempt restoration of retinal perfusion and urgently identify and treat the systemic vascular source.
Immediate Emergency Measures
| Measure | Rationale / Detail |
|---|---|
| Confirm onset time and document vision | Establish exact time of onset, visual acuity, RAPD, and fundus findings. |
| Digital ocular massage | Firm intermittent pressure over closed lids, such as 5 seconds on and 5 seconds off for 5–10 minutes, aiming to dislodge embolus and alter retinal perfusion pressure. |
| IOP lowering | Topical beta-blocker and IV acetazolamide 500 mg stat may be used to lower IOP and improve perfusion gradient. |
| Anterior chamber paracentesis | Rapidly reduces IOP; may be considered early under topical anaesthesia, though evidence for visual benefit is limited. |
| Oxygen / carbogen | 100% oxygen or carbogen has been used to increase oxygen delivery and cause vasodilation, but evidence is limited. |
| Paper-bag rebreathing | Historically used to raise CO2 and produce vasodilation; now largely abandoned because evidence is poor. |
| Haemodilution / pentoxifylline | Occasionally used in some centres; evidence remains limited. |
Thrombolysis Evidence
Intra-arterial thrombolysis: The corrected EAGLE trial citation is Schumacher M, Schmidt D, Jurklies B, et al.; EAGLE-Study Group. Ophthalmology. 2010;117(7):1367-75.e1; PMID 20609991. This multicentre RCT found no significant visual benefit of local intra-arterial fibrinolysis over conservative treatment (p=0.69), with a substantially higher adverse event rate in the IAT arm (37.1% vs 4.3%). Therefore, intra-arterial fibrinolysis is not recommended as standard CRAO treatment.
Intravenous thrombolysis: The REVISION trial (NCT04965038) is a phase III double-blind RCT evaluating IV alteplase versus placebo within 4.5 hours of non-arteritic CRAO onset, with functional visual recovery at 30 days as a key endpoint. Until definitive results are available, IV alteplase remains a stroke-centre protocol decision in selected patients within the time window and without contraindications.
Systemic and Long-Term Management
- Urgent stroke unit or neurology referral for systemic evaluation and prevention of cerebral stroke.
- Antiplatelet therapy such as aspirin for atherosclerotic or embolic CRAO, as directed by stroke physicians.
- Anticoagulation when a cardioembolic source such as atrial fibrillation or a high-risk hypercoagulable state is identified.
- Aggressive vascular risk factor control: hypertension, diabetes, dyslipidaemia, smoking cessation, obesity, and lifestyle measures.
- High-intensity statin therapy when atherosclerotic disease is present or suspected.
- Carotid endarterectomy or carotid stenting may be indicated for significant symptomatic ipsilateral carotid stenosis, especially >70%, after vascular specialist assessment.
- If GCA is suspected, give urgent systemic corticosteroids: IV methylprednisolone in high-risk visual presentations followed by oral prednisolone, with temporal artery biopsy or vascular imaging arranged promptly.
Management of Complications
| Complication | Management |
|---|---|
| Rubeosis iridis / neovascular glaucoma | Regular slit-lamp and gonioscopy follow-up; pan-retinal photocoagulation if neovascularisation develops; anti-VEGF as adjunct; IOP control if NVG occurs. |
| Neovascularisation of disc or retina | Pan-retinal photocoagulation, similar to other retinal ischaemic neovascular states. |
| Concurrent stroke or TIA | Urgent stroke-unit admission and management according to acute stroke protocol. |
| Fellow eye risk | Treat systemic vascular risk factors and arrange follow-up. |
| Scenario | Prognosis |
|---|---|
| Complete CRAO without cilioretinal sparing | Severe visual loss at presentation; visual recovery is usually poor. |
| CRAO with cilioretinal artery sparing | Vision may recover well in the spared territory, sometimes to 6/12–6/6 depending on macular perfusion. |
| Branch retinal artery occlusion | Visual outcome is variable and depends mainly on macular involvement; field defect may persist. |
| Early stroke risk | Approximately 2–5% risk of stroke in the first week, supporting urgent systemic work-up. |
| Long-term stroke risk | Ongoing elevated cerebrovascular risk requires secondary prevention. |
| Neovascular glaucoma | Rubeosis or NVG may occur in approximately 20% within 1–3 months, so follow-up is mandatory. |
| Differential | Distinguishing Features |
|---|---|
| Central retinal vein occlusion | Dilated tortuous veins, flame haemorrhages, disc oedema, variable VA; no classic cherry-red spot. |
| Ischaemic anterior optic neuropathy | Disc oedema, altitudinal visual field defect, often less profound VA loss than CRAO; GCA association in arteritic cases. |
| Optic neuritis | Pain on eye movement, young patient, central scotoma, RAPD; no retinal whitening. |
| Commotio retinae | History of trauma with Berlin oedema causing retinal whitening. |
| Methanol toxicity | Usually bilateral with metabolic acidosis and optic disc involvement rather than unilateral retinal arterial whitening. |
| Vitreous haemorrhage | Sudden visual loss with obscured fundus view; B-scan helps differentiate. |
CRAO is a time-critical ocular stroke with a narrow therapeutic window and poor visual prognosis once established. The ophthalmologist must attempt early reperfusion when appropriate, exclude arteritic CRAO, identify complications such as rubeosis, and coordinate urgent stroke-level systemic evaluation. The EAGLE trial argues against routine intra-arterial fibrinolysis, while ongoing IV alteplase trials such as REVISION may further define the future acute treatment pathway.
Trap 1 — TRUE
“Always exclude giant cell arteritis in patients over 50 years presenting with CRAO.”
Arteritic CRAO requires urgent systemic corticosteroids and GCA work-up; thrombolysis is not the primary treatment pathway.
Trap 2 — FALSE
“The cherry-red spot in CRAO is a true colour change of the fovea.”
It is normal choroidal flush seen through the thin avascular fovea, contrasted against surrounding opaque oedematous retina.
Trap 3 — FALSE
“Gaucher disease is a classic cherry-red spot differential.”
Remove Gaucher disease from the cherry-red spot list. Storage disorders with cherry-red spot include Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A, GM1 gangliosidosis, Farber disease, and sialidosis type 1.
Trap 4 — FALSE
“Cattle-trucking is pathognomonic of CRAO.”
Cattle-trucking is segmentation of the retinal arterial blood column due to sluggish flow and can also be seen in severe anaemia or hyperviscosity states.
Trap 5 — TRUE
“ERG in CRAO shows reduced b-wave with relatively preserved a-wave.”
The b-wave reflects inner retinal function and is reduced in CRAO; the a-wave is relatively preserved because photoreceptors are supplied by the choroidal circulation.
Trap 6 — FALSE
“EAGLE trial supports routine intra-arterial fibrinolysis for CRAO.”
Corrected EAGLE trial: Schumacher M et al., Ophthalmology 2010;117(7):1367-75.e1. It showed no significant visual benefit of local intra-arterial fibrinolysis over conservative treatment and higher adverse events.
Trap 7 — FALSE
“REVISION trial registration number is NCT03792165.”
The corrected REVISION trial registration number is NCT04965038. It is a phase III RCT of IV alteplase versus placebo within 4.5 hours of non-arteritic CRAO onset.
Trap 8 — TRUE
“Superior BRAO causes an inferior visual field defect.”
Retinal and visual field localisation are inverted; superior retinal ischaemia produces an inferior field defect.
Trap 9 — TRUE
“Rubeosis after CRAO usually requires surveillance during the first 1–3 months.”
NVI/NVA and neovascular glaucoma can develop after CRAO, so slit-lamp and gonioscopy follow-up are mandatory.
Trap 10 — TRUE
“Young CRAO should trigger an extended systemic work-up.”
In patients under 40 years, consider antiphospholipid syndrome, inherited thrombophilia, PFO, oral contraceptive pill association, migraine, cocaine use, and syphilis.
Q: Why does a cherry-red spot appear in CRAO?
A: The surrounding inner retina becomes opaque from cytotoxic oedema, while the thin avascular fovea still shows normal choroidal colour.
Q: Which retinal layers are primarily affected in CRAO?
A: The inner retinal layers supplied by the central retinal artery, especially the nerve fibre layer, ganglion cell layer, inner plexiform layer, and inner nuclear layer.
Q: Why is the a-wave relatively preserved on ERG in CRAO?
A: The a-wave reflects photoreceptor function, and photoreceptors are supplied mainly by the choroidal circulation rather than the central retinal artery.
Q: What is the most important systemic diagnosis to exclude in an older patient with CRAO?
A: Giant cell arteritis, because it requires urgent systemic corticosteroids to protect the fellow eye and prevent systemic complications.
Q: What does a Hollenhorst plaque indicate?
A: A cholesterol embolus, usually from ipsilateral carotid atherosclerosis, requiring urgent carotid and vascular risk evaluation.
Q: What is the OCT signature of acute CRAO?
A: Inner retinal hyperreflectivity and oedema acutely, followed later by inner retinal thinning, especially GCL-IPL thinning.
Q: What is the key corrected EAGLE trial message?
A: Local intra-arterial fibrinolysis did not improve visual outcome compared with conservative treatment and caused more adverse events.
Q: What is the corrected REVISION trial identifier?
A: NCT04965038; it studies IV alteplase versus placebo within 4.5 hours of non-arteritic CRAO onset.
References
- Conservative medical knowledge — cherry-red spot requires perifoveal ganglion cell sphingolipid/ganglioside accumulation causing opacification; Gaucher's disease (glucocerebrosidase deficiency) causes glucocerebroside accumulation without the classic cherry-red spot fundoscopic appearance; major ophthalmology references (Yanoff & Duker,
- AAO BCSC Section 12) do not list Gaucher's in the cherry-red spot differential.
- PMID 20609991 — Schumacher M, Schmidt D, Jurklies B, et al; EAGLE-Study Group. Ophthalmology. 2010;117(7):1367-75.e1. doi:10.1016/j.ophtha.2010.03.061
- Poli S et al. Int J Stroke. 2024 (PMID 38591748) — explicitly states: 'Trial registration: ClinicalTrials.gov: NCT04965038; EU Trial Number: 2023-507388-21-00.' Also confirmed via CenterWatch listing for NCT04965038.
- Poli S et al. Int J Stroke. 2024 (PMID 38591748) — explicitly states: 'Trial registration: ClinicalTrials.gov: NCT04965038; EU Trial Number: 2023-507388-21-00.'
- Schmidt D, Schumacher M, Wakhloo AK. Am J Ophthalmol. 2008;147(3):410-418.
- Hayreh SS. Br J Ophthalmol. 1965;49(12):626-645.
- Hayreh's seminal 1965 Br J Ophthalmol paper on retinal vessel occlusion is a real publication; specific page numbers unverifiable in fast mode.